MiR-509-3-5p causes aberrant mitosis and anti-proliferative effect by suppression of PLK1 in human lung cancer A549 cells

Biochem Biophys Res Commun. 2016 Sep 16;478(2):676-82. doi: 10.1016/j.bbrc.2016.08.006. Epub 2016 Aug 3.

Abstract

MicroRNAs (miRNAs) are potent post-transcriptional regulators of gene expression and play roles in DNA damage response (DDR). PLK1 is identified as a modulator of DNA damage checkpoint. Although down-regulation of PLK1 by certain microRNAs has been reported, little is known about the interplay between PLK1 and miR-509-3-5p in DDR. Here we have demonstrated that miR-509-3-5p repressed PLK1 expression by targeting PLK1 3'-UTR, thereby causing mitotic aberration and growth arrest of human lung cancer A549 cells. Repression of PLK1 by miR-509-3-5p was further evidenced by over-expression of miR-509-3-5p in A549, HepG2 and HCT116p53(-/-) cancer cells, in which PLK1 protein was suppressed. Consistently, miR-509-3-5p was stimulated, while PLK1 protein was down-regulated in A549 cells exposed to CIS and ADR, suggesting that suppression of PLK1 by miR-509-3-5p is a component of CIS/ADR-induced DDR pathway. Flow cytometry and immunofluorescence labeling showed that over-expression of miR-509-3-5p in A549 induced G2/M arrest and aberrant mitosis characterized by abnormal bipolar mitotic spindles, condensed chromosomes, lagging DNA and chromosome bridges. In addition, over-expression of miR-509-3-5p markedly blocked A549 cell proliferation and sensitized the cells to CIS and ADR treatment. Taken together, miR-509-3-5p is a feasible suppressor for cancer by targeting PLK1. Our data may provide aid in potential design of combined chemotherapy and in our better understanding of the roles of microRNAs in response to DNA damage.

Keywords: Aberrant mitosis; Adriamycin; Cisplatin; DNA damage response; PLK1; miR-509-3-5p.

MeSH terms

  • 3' Untranslated Regions
  • A549 Cells
  • Antibiotics, Antineoplastic / pharmacology
  • Apoptosis / drug effects
  • Base Sequence
  • Cell Cycle Proteins / antagonists & inhibitors
  • Cell Cycle Proteins / genetics*
  • Cell Cycle Proteins / metabolism
  • Cell Proliferation / drug effects
  • Cisplatin / pharmacology
  • Doxorubicin / pharmacology
  • G2 Phase Cell Cycle Checkpoints / drug effects
  • Gene Expression Regulation, Neoplastic*
  • HCT116 Cells
  • Hep G2 Cells
  • Humans
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Mitosis / drug effects
  • Polo-Like Kinase 1
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Protein Serine-Threonine Kinases / genetics*
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins / antagonists & inhibitors
  • Proto-Oncogene Proteins / genetics*
  • Proto-Oncogene Proteins / metabolism
  • Signal Transduction

Substances

  • 3' Untranslated Regions
  • Antibiotics, Antineoplastic
  • Cell Cycle Proteins
  • MIRN509 microRNA, human
  • MicroRNAs
  • Proto-Oncogene Proteins
  • Doxorubicin
  • Protein Serine-Threonine Kinases
  • Cisplatin